PhD Candidate @Penn | @carlhjune lab | MSc @DrexelUniv | @FulbrightPrgrm Scholar 2018 | Pharmaceutical Chemist @Udelaruy @FqUdelar
Joined April 2020
- Tweets105
- Following274
- Followers112
- Likes503
Sofía Castelli retweeted
IL-9, the little-known cytokine, finally found its calling, helping CAR T cells take on solid tumors. More staying power, more memory, more punch.
#science
#immunology
cell.com/immunity/abstract/S…
Sofía Castelli retweeted
New in @ImmunityCP: @msofiacastelli and a team in the @carlhjune lab engineered CAR T cells with IL-9 signaling to boost efficacy against #SolidTumors.
bit.ly/48vJql0
Sofía Castelli retweeted
IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy: Immunity @parkerici @PennMedicine cell.com/immunity/abstract/S…
Sofía Castelli retweeted
Engineering T cells (CAR T) for treatment of solid cancers has had mixed success to date. Two reports today raise the promise of using interleukin-9 as a way to raise efficacy @ImmunityCP
cell.com/immunity/fulltext/S…
cell.com/immunity/fulltext/S…
Sofía Castelli retweeted
Report of note: IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy
•Engineering CAR T cells with IL-9 signaling boosts efficacy against solid tumors
•IL-9-signaling CD4+ CAR T cells have increased Th1 and proliferative phenotypes
•Single-cell profiling reveals that IL-9 redirects CD8+ T cell fate away from dysfunction
•IL-9-induced STAT1/STAT4 activation contributes to improved CAR T cell function cell.com/immunity/fulltext/S…
Sofía Castelli retweeted
Online now: IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy dlvr.it/TPPKLL
Sofía Castelli retweeted
IL-9 enhancement of engineered CAR-T therapies
@ImmunityCP @carlhjune @msofiacastelli
@Penn @xrtcell @stanford @KaylaKulhanek
cell.com/immunity/fulltext/S…
cell.com/immunity/fulltext/S…
Sofía Castelli retweeted
🚨Coming soon! Multiplex engineering using microRNA-mediated gene silencing in CAR T cells. In a single lentiviral vector- multiplex silencing & expression of a CAR, better expansion & viability than gene editing by electroporation @PennMedicine antionbio.com @FrontiersIn frontiersin.org/journals/imm…
Sofía Castelli retweeted
A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients with B-cell lymphoma who had exhausted other treatment options ft. @carlhjune (@PennPathLabMed) & Jakub Svoboda (@PennCancer) @UPenn_I3H tinyurl.com/3ejw9334
Sofía Castelli retweeted
Congratulations to our own Drs. June and Levine!
Carl June (@Penn), Bruce Levine (Penn), Isabelle Rivière (@TakedaPharma), Michel Sadelain (@Columbia) have been awarded the 2025 Richard N. Merkin Prize in Biomedical Technology for developing CAR T-cell therapy for cancer. broad.io/MerkinPrizeNews2025
Sofía Castelli retweeted
Penn researchers found that next-generation IL18-armored #CARTCellTherapy shows promise for patients whose #lymphoma resisted multiple other cancer treatments, including commercial CAR T cell therapies. @carlhjune @NEJM @AACR #NCRM #UnitedByCancerResearch spr.ly/6019NpiON
Sofía Castelli retweeted
CAR T-cell therapy isn’t just a breakthrough—it’s a lifeline. A new PICI-supported review in @MolTherapy by @carlhjune, Director of the PICI Center at @PennMedicine, and team traces the decades of research that made engineered immune cells a powerful cancer treatment. cell.com/molecular-therapy-f…
Sofía Castelli retweeted
CAR T-cell therapy has transformed treatment for 35K+ patients, with a well-established safety profile. New in @TheLancet: @carlhjune, Director of the PICI Center at @PennMedicine, @BLLPHD & @daniel_baker_j explore latest data and what’s next in the field. thelancet.com/journals/lance…
Sofía Castelli retweeted
Crystal Mackall and Carl June discussed groundbreaking strategies to enhance CAR T-cell therapies, pushing the boundaries for solid cancer treatment on day 3 of #AACRIO25. Learn more on the #AACRBlog: brnw.ch/21wR0gf @parkerici @PennMedicine
Sofía Castelli retweeted
IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing anti-tumor efficacy
doi.org/10.1101/2025.01.30.6…
@carlhjune @msofiacastelli
Sofía Castelli retweeted
IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing anti-tumor efficacy biorxiv.org/content/10.1101/… #biorxiv_immuno
Sofía Castelli retweeted
The 2024 @vinfutureprize Special Prize for Innovators with Outstanding Achievements in Emerging Fields was awarded last month to Zelig Eshhar, @PennCancer's @carlhjune, and Michel Sadelain for development of #CARTCellTherapy for cancer and other diseases. spr.ly/6017aS2N7
Sofía Castelli retweeted
Penn Medicine’s clinical research teams are hidden heroes of #CARTcelltherapy. From taking care of patients at the bedside to collecting and analyzing data, their work is vital to moving innovative research forward. spr.ly/6015aR87Z
Sofía Castelli retweeted
Congrats @msofiacastelli @PennMedicine on being named a Representation in SciencE (RISE) Scholar award recipient @parkerici
Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research parkerici.org/the-latest/par…
